Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Flattish volume growth and subdued new launches were key factors for last month
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
This is Enzene Biosciences third biosimilar to be approved
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)